Single center experience in primary surgery for medullary thyroid carcinoma

World Journal of Surgery

Volumn 28, Issue 12, 2004, Pages 1271-1274

  Ukkat, Jörg ^a   Gimm, Oliver ^a   Brauckhoff, Michael ^a   Bilkenroth, Udo ^a   Dralle, Henning ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; ONCOPROTEIN; PROTEIN RET; PROTEIN TYROSINE KINASE; RET PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER SURGERY; CHILD; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; BLOOD; GENETICS; INFANT; LYMPHADENECTOMY; MEDULLARY CARCINOMA; MIDDLE AGED; MUTATION; PRESCHOOL CHILD; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; CALCITONIN; CARCINOMA, MEDULLARY; CHILD; CHILD, PRESCHOOL; GERM-LINE MUTATION; HUMANS; INFANT; LYMPH NODE EXCISION; MALE; MIDDLE AGED; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 16644374394     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-004-7608-9     Document Type: Article

References (25)

1. Tisell LE, Hansson G, Jansson S, et al. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986;99:60-66
2. Van Heerden JA, Grant CS, Gharib H, et al. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann. Surg. 1990;212:395-400
3. Moley JF, Wells SA, Dilley WG, et al. Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 1993;114:1090-1095
4. Dralle H, Damm I, Scheumann GFW, et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg. Today 1994;24:112-121
5. Dottorini ME, Assi A, Sironi M, et al. Multivariate analysis of patients with medullary thyroid carcinoma: prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 1996;77:1556-1565
6. Gimm O, Ukkat J, Dralle H. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J. Surg. 1998;22:562-567
7. Brauckhoff M, Gimm O, Brauckhoff K, et al. Calcitonin kinetics in the early postoperative period of medullary thyroid carcinoma. Langenbecks Arch. Surg. 2001;386:434-439
8. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. J.A.M.A. 1996;276:1575-1579
9. Donis-Keller H, Dou S, Chi D, et al. Mutations of the RET protooncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 1993;2:851-856
10. Mulligan LM, Kwok JB, Healey CS, et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-460
11. Schuffenecker I, Chambe B, Lenoir G. Analysis of the RET gene and medullary cancer of the thyroid: contribution to the diagnosis and treatment. Ann. Endocrinol. (Paris) 1996;57:9-14
12. Dralle H, Gimm O, Simon D, et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J. Surg. 1998;22:744-751
13. Ukkat J, Lorenz K, Hinze R, et al. Importance of early screening and prophylactic thyroidectomy in asymptomatic nonindex RET germline carriers. World J. Surg. 2001;25:713-717
14. Dralle H, Scheumann GF, Proye C, et al. The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study. J. Intern. Med. 1995;238:357-361
15. Wells SA, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann. Surg. 1994;220:237-250
16. Hinze R, Holzhausen HJ, Gimm O, et al. Primary hereditary medullary thyroid carcinoma: C-cell morphology and correlation with preoperative calcitonin levels. Virchows Arch. 1998;433:203-208
17. Wolfe HJ, Melvin KE, Cervi-Skinner SJ, et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N. Engl. J. Med. 1973;289:437-441
18. DeLellis RA. Proliferation markers in neuroendocrine tumors: useful or useless? A critical reappraisal. Verh. Dtsch. Ges. Pathol. 1997;81:53-61
19. Sobin LH, Wittekind C, editors. TNM Classification of Malignant Tumours, New York, Wiley, 1997;47-50
20. Dralle H, Scheumann GF, Kotzerke J, et al. Surgical management of MEN 2. Recent Results Cancer Res. 1992;125:167-195
21. Bergholm U, Bergström R, Ekborn A. Long term follow-up of patients with medullary carcinoma of the thyroid. Cancer 1997;79:132
22. Dralle H, Damm I, Scheumann GF, et al. Frequency and significance of cervicomediastinal lymph node metastases in medullary thyroid carcinoma: results of a compartment-oriented microdissection method. Henry Ford Hosp. Med. J. 1992;40:264
23. Girelli ME, Dotto S, Nacamulli D, et al. Prognostic value of early post-operative calcitonin level in medullary thyroid carcinoma. Tumori 1994;80:113
24. Thomusch O, Machens A, Sekulla C, et al. Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J. Surg. 2000;24:1335-1341
25. Heshmati HM, Gharib H, van Heerden JA, et al. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am. J. Med. 1997;103:60-69